Ensign Peak Advisors
CRL icon

Ensign Peak Advisors’s Charles River Laboratories CRL Stock Holding History

Ensign Peak Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$680K Hold
2,999
– – ﹤0.01% 905
2026
Q1 		$517K Hold
2,999
– – ﹤0.01% 954
2025
Q4 		$598K Sell
2,999
-7,750
-72% -$1.41M ﹤0.01% 916
2025
Q3 		$1.68M Sell
10,749
-3,100
-22% -$492K ﹤0.01% 850
2025
Q2 		$2.1M Sell
13,849
-850
-6% -$113K ﹤0.01% 883
2025
Q1 		$2.21M Sell
14,699
-1,423
-9% -$239K ﹤0.01% 863
2024
Q4 		$2.98M Hold
16,122
– – 0.01% 798
2024
Q3 		$3.18M Buy
16,122
+400
+3% +$83.1K 0.01% 772
2024
Q2 		$3.25M Hold
15,722
– – 0.01% 753
2024
Q1 		$4.26M Sell
15,722
-141
-0.9% -$33.7K 0.01% 672
2023
Q4 		$3.75M Sell
15,863
-4,249
-21% -$836K 0.01% 700
2023
Q3 		$3.94M Sell
20,112
-188
-0.9% -$38.6K 0.01% 635
2023
Q2 		$4.27M Buy
20,300
+500
+3% +$99.5K 0.01% 631
2023
Q1 		$4M Sell
19,800
-4,604
-19% -$1.04M 0.01% 633
2022
Q4 		$5.32M Buy
24,404
+9,091
+59% +$1.99M 0.01% 546
2022
Q3 		$3.01M Sell
15,313
-3,154
-17% -$681K 0.01% 651
2022
Q2 		$3.95M Buy
18,467
+150
+0.8% +$36.7K 0.01% 599
2022
Q1 		$5.2M Sell
18,317
-2,175
-11% -$671K 0.01% 580
2021
Q4 		$7.72M Buy
20,492
+13,615
+198% +$5.29M 0.01% 532
2021
Q3 		$2.84M Buy
6,877
+3,487
+103% +$1.45M 0.01% 913
2021
Q2 		$1.25M Sell
3,390
-45,519
-93% -$15.2M ﹤0.01% 1354
2021
Q1 		$14.2M Sell
48,909
-213
-0.4% -$59.2K 0.03% 359
2020
Q4 		$12.3M Sell
49,122
-1,072
-2% -$255K 0.03% 387
2020
Q3 		$11.4M Buy
50,194
+5,240
+12% +$1.09M 0.03% 420
2020
Q2 		$7.84M Buy
44,954
+4,830
+12% +$771K 0.02% 481
2020
Q1 		$5.06M Sell
40,124
-2,430
-6% -$364K 0.02% 509
2019
Q4 		$6.5M Buy
+42,554
New +$5.89M 0.02% 564

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Ensign Peak Advisors's CRL Position: Q2 2026 in Review

Ensign Peak Advisors held its Charles River Laboratories (CRL) position steady in Q2 2026 at 2,999 shares worth $680K. The position accounts for ﹤0.01% of the portfolio, ranked #905.

Ensign Peak Advisors first reported a position in CRL in Q4 2019 and has held it in 27 quarters since. The position peaked at $14.2M in Q1 2021. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Ensign Peak Advisors held 2,999 shares of Charles River Laboratories worth $680K as of Q2 2026.
  • Ensign Peak Advisors left its Charles River Laboratories share count unchanged in Q2 2026.
  • Charles River Laboratories made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #905 holding.
  • Ensign Peak Advisors first reported a position in Charles River Laboratories in Q4 2019 and has held it in 27 quarters since.
  • Ensign Peak Advisors's Charles River Laboratories position peaked at $14.2M in Q1 2021.
  • 565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.